ReviewOpen biology2019
Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?
Review in Open biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A proposal of a new periimplant breast pathology classification into 3 types.Scientific reports · 2026Article
- [Pathologies of joint endoprostheses : Histopathological diagnostics for endoprosthetic centers].Pathologie (Heidelberg, Germany) · 2025Article
- Oxylipins in Breast Implant-Associated Systemic Symptoms.Aesthetic surgery journal · 2024Article
- Anaplastic lymphoma associated with breast implants-Early diagnosis and treatment.Clinical case reports · 2023Article
- The evaluation of the delayed swollen breast in patients with a history of breast implants.Frontiers in oncology · 2023Review
- 2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCL.Aesthetic surgery journal · 2022Review
- Review
- ESSM Position Statement "Sexual Wellbeing After Gender Affirming Surgery".Sexual medicine · 2022Review
- Microbial community compositions in breast implant biofilms associated with contracted capsules.PloS one · 2021Article
- An experimental study on the prosthesis produced by inactivated autologous subcutaneous adipose tissue and skin dermal tissue in a mini-pig model.Translational cancer research · 2020Article
- Article
- The Emerging Crisis of Stakeholders in Implant-based Augmentation Mammaplasty in Korea.Journal of Korean medical science · 2020Article
- Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.The American journal of pathology · 2020Review
- Silicone nipple discharge: A case report of an unusual presentation of breast implant rupture.International journal of surgery case reports · 2020Article
- A Rare Case of Breast Implant-Associated Diffuse Large B-Cell Lymphoma.Case reports in oncological medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) may occur after reconstructive or aesthetic breast surgery. Worldwide, approximately 1.7 million breast implant surgeries are performed each year. To date, over 500 cases of BIA-ALCL have been reported around the world, with 16 women having died. This review highlights the most important facts surrounding BIA-ALCL. There is no consensus regarding the true incidence rate of BIA-ALCL as it varies between countries, is probably significantly under-reported and is difficult to estimate due to the true number of breast prostheses used largely being unknown. BIA-ALCL develops in the breast mostly as a seroma surrounding the implant, but contained within the fibrous capsule, or more rarely as a solid mass that can become invasive infiltrating the chest wall and muscle, in some instances spreading to adjacent lymph nodes, in these cases having a far worse prognosis. The causation of BIA-ALCL remains to be established, but it has been proposed that chronic infection and/or implant toxins may be involved. What is clear is that complete capsulectomy is required for treatment of BIA-ALCL, which for early-stage disease leads to cure, whereas chemotherapy is needed for advanced-stage disease, whereby improved results have been reported with the use of brentuximab. A worldwide database for BIA-ALCL and implants should be supported by local governments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.